Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer.

30 An issue, which is already relevant to patient groups receiving these agents in routine clinical practice, since benefit on OS with addition of bevacizumab is often borderline significant or lacking depending on the chemotherapy regimen. 31 – 33 Better understanding of these mechanisms will make it possible to identify sensitive targets and/or phenotypes to overcome these tumour escape mechanisms.

also in 11,409 other papers